Published in Antimicrob Agents Chemother on November 21, 2016
Controlling schistosomiasis with praziquantel: How much longer without a viable alternative? Infect Dis Poverty (2017) 0.75
Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis (2006) 13.74
Human schistosomiasis. Lancet (2006) 10.87
Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet (2005) 9.45
Artemisinins target the SERCA of Plasmodium falciparum. Nature (2003) 7.72
The global status of schistosomiasis and its control. Acta Trop (2000) 6.89
Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop (2003) 6.64
Identification of an antimalarial synthetic trioxolane drug development candidate. Nature (2004) 4.57
Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A (2011) 3.23
The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008. Parasitology (2009) 3.03
Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol (2002) 2.91
The molecular mechanism of action of artemisinin--the debate continues. Molecules (2010) 2.57
A medicinal chemistry perspective on artemisinin and related endoperoxides. J Med Chem (2004) 2.42
Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Trop Med Hyg (1994) 2.25
From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop (2010) 2.01
The drugs we have and the drugs we need against major helminth infections. Adv Parasitol (2010) 1.93
The antimalarial drug artemisinin alkylates heme in infected mice. Proc Natl Acad Sci U S A (2005) 1.81
In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology (2009) 1.79
Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni. Parasitology (2009) 1.60
Vaccines to combat the neglected tropical diseases. Immunol Rev (2011) 1.55
In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. Antimicrob Agents Chemother (2007) 1.52
Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg (1996) 1.47
Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J Pharm Sci (1999) 1.45
Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol Med (2006) 1.42
Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol (2014) 1.40
Are Ca2+ channels targets of praziquantel action? Int J Parasitol (2004) 1.36
Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Curr Opin Infect Dis (2007) 1.32
Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem (1998) 1.21
Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. Int J Parasitol (2004) 1.20
Why artemisinin and certain synthetic peroxides are potent antimalarials. Implications for the mode of action. Curr Med Chem (2001) 1.18
Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. PLoS Negl Trop Dis (2012) 1.17
First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol (2013) 1.15
Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro. J Antimicrob Chemother (2011) 1.10
Iron-mediated degradation kinetics of substituted dispiro-1,2,4-trioxolane antimalarials. J Pharm Sci (2007) 1.09
Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium. PLoS Negl Trop Dis (2012) 1.08
Heme as trigger and target for trioxane-containing antimalarial drugs. Acc Chem Res (2010) 1.08
Schistosomiasis: number of people treated worldwide in 2013. Wkly Epidemiol Rec (2015) 1.07
Praziquantel analogs with activity against juvenile Schistosoma mansoni. Bioorg Med Chem Lett (2010) 1.06
Genetic analysis of decreased praziquantel sensitivity in a laboratory strain of Schistosoma mansoni. Acta Trop (2009) 1.03
Schistosoma mansoni: lack of correlation between praziquantel-induced intra-worm calcium influx and parasite death. Exp Parasitol (2008) 1.00
Structure-activity relationship of an ozonide carboxylic acid (OZ78) against Fasciola hepatica. J Med Chem (2010) 1.00
The synthetic peroxide OZ78 is effective against Echinostoma caproni and Fasciola hepatica. J Antimicrob Chemother (2006) 1.00
Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni. Antimicrob Agents Chemother (2014) 0.96
Schistosome vaccines: a critical appraisal. Mem Inst Oswaldo Cruz (2006) 0.95
Schistosoma mansoni: a method for inducing resistance to praziquantel using infected Biomphalaria glabrata snails. Mem Inst Oswaldo Cruz (2011) 0.94
Fitting heteroscedastic regression models to individual pharmacokinetic data using standard statistical software. J Pharmacokinet Biopharm (1989) 0.93
Schistosoma japonicum-infected hamsters (Mesocricetus auratus) used as a model in experimental chemotherapy with praziquantel, artemether, and OZ compounds. Parasitol Res (2010) 0.90
Praziquantel derivatives I: Modification of the aromatic ring. Bioorg Med Chem Lett (2007) 0.89
Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciola hepatica. J Antimicrob Chemother (2009) 0.89
Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica. Trans R Soc Trop Med Hyg (2007) 0.87
Characterization of the two major CYP450 metabolites of ozonide (1,2,4-trioxolane) OZ277. Bioorg Med Chem Lett (2008) 0.87
In vivo activity of aryl ozonides against Schistosoma species. Antimicrob Agents Chemother (2011) 0.86
Clonorchicidal properties of the synthetic trioxolane OZ78. J Parasitol (2007) 0.86
Efficacy, safety and pharmacokinetics of 1,2,4-trioxolane OZ78 against an experimental infection with Fasciola hepatica in sheep. Vet Parasitol (2010) 0.86
Synthesis of new praziquantel analogues: potential candidates for the treatment of schistosomiasis. Bioorg Med Chem Lett (2011) 0.86
In vitro and in vivo activity of 3-alkoxy-1,2-dioxolanes against Schistosoma mansoni. J Antimicrob Chemother (2012) 0.85
Quantum chemical study of the intermediate complex required for iron-mediated reactivity and antimalarial activity of dispiro-1,2,4-trioxolanes. J Mol Graph Model (2008) 0.83
Community acceptability of the use of low-dose niclosamide (Bayluscide), as a molluscicide in the control of human schistosomiasis in Sahelian Cameroon. Ann Trop Med Parasitol (2007) 0.81
Amino ozonides exhibit in vitro activity against Echinococcus multilocularis metacestodes. Int J Antimicrob Agents (2013) 0.80
Synthetic peroxides as potent antimalarials. News and views. Curr Top Med Chem (2012) 0.79
Effectiveness of synthetic trioxolane OZ78 against Schistosoma japonicum in mice and rabbits. Parasitol Res (2011) 0.79
Development and validation of a liquid chromatography/mass spectrometry method for pharmacokinetic studies of OZ78, a fasciocidal drug candidate. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.79
Pharmacokinetics of the fasciocidal drug candidates MT04 and OZ78 in uninfected rats and in vitro pharmacodynamic studies. Int J Parasitol Drugs Drug Resist (2012) 0.78
The relative influences of acidity and polarity on responsiveness of small organic molecules to analysis with negative ion electrospray ionization mass spectrometry (ESI-MS). J Am Soc Mass Spectrom (2005) 0.78
Macromolecular bases of antischistosomal therapy. Curr Top Med Chem (2011) 0.77
[Progress in development of new antischistosomal drugs in recent years]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (2010) 0.76
Efficacy and pharmacokinetics of OZ78 and MT04 against a natural infection with Fasciola hepatica in sheep. Vet Parasitol (2013) 0.76
Effect of ozonide OZ418 against Schistosoma japonicum harbored in mice. Parasitol Res (2014) 0.76
Simultaneous determination of OZ277, a synthetic 1,2,4-trioxolane antimalarial, and its polar metabolites in rat plasma using hydrophilic interaction chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.76
Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled trial. Lancet Infect Dis (2015) 1.70
Efficacy and safety of oxantel pamoate in school-aged children infected with Trichuris trichiura on Pemba Island, Tanzania: a parallel, randomised, controlled, dose-ranging study. Lancet Infect Dis (2015) 1.45
Current in vitro Methods to Determine Hepatic Kpuu: a Comparison of Their Usefulness and Limitations. J Pharm Sci (2017) 0.80
Single-Ascending-Dose Pharmacokinetic Study of Tribendimidine in Opisthorchis viverrini-Infected Patients. Antimicrob Agents Chemother (2016) 0.78
Evaluation of an FDA approved library against laboratory models of human intestinal nematode infections. Parasit Vectors (2016) 0.75
Pharmacokinetic Study of Praziquantel Enantiomers and Its Main Metabolite R-trans-4-OH-PZQ in Plasma, Blood and Dried Blood Spots in Opisthorchis viverrini-Infected Patients. PLoS Negl Trop Dis (2016) 0.75
Mechanisms of increased bioavailability through amorphous solid dispersions: a review. Drug Deliv (2020) 0.75
Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model. PLoS Negl Trop Dis (2017) 0.75
Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles-Differential Centrifugation and FACS. Pharm Res (2015) 0.75
In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium. Parasit Vectors (2017) 0.75